Clinical Resource: CDK4/6 Inhibitor Therapy in HR+, HER2– Breast Cancer
CDK4/6 inhibitors have proven effective in the first- and second-line treatment of early and metastatic HR+, HER2– breast cancer. The available CDK4/6 inhibitors have clinically relevant differences in their indications, dosing schedules, monitoring recommendations, and toxicity profiles. This comprehensive clinical resource, developed by a team of multidisciplinary oncology healthcare providers, is intended to support oncology nurses and pharmacists in the routine clinical management of patients beginning or receiving CDK4/6 inhibitors.